Imipenem versus piperacillin/tazobactam for empiric treatment of febrile neutropenia in adults.
Intern Med J. 2013 Jun 26;
Authors: Roohullah A, Moniwa A, Wood C, Humble M, Balm M, Carter J, Weinkove R
Australian guidelines for febrile neutropenia recommend piperacillin/tazobactam (PIP-TAZ) or cefepime for first-line empiric treatment of febrile neutropenia. We compared outcomes among haematology patients before and after changing our first-line febrile neutropenia treatment from imipenem to PIP-TAZ. Forty-five patients received imipenem and 60 PIP-TAZ. Despite a higher rate of antibiotic modification in the PIP-TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer Clostridium difficile infections in the PIP-TAZ cohort.
PMID: 23800137 [PubMed - as supplied by publisher]